CoChat

Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade

Open access
Flaig, Thomas W., Salzmann-Sullivan, Maren, Su, Lih-Jen, Zhang, Zhiyong, Joshi, Molishree, Gijón, Miguel A., Kim, Jihye, Arcaroli, John J., Van Bokhoven, Adrie, Lucia, M. Scott, La Rosa, Francisco G., Schlaepfer, Isabel R. · 2017 · Oncotarget
Cited by 99

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

// Thomas W. Flaig 1 , Maren Salzmann-Sullivan 1 , Lih-Jen Su 1 , Zhiyong Zhang 1 , Molishree Joshi 2 , Miguel A. Gijón 2 , Jihye Kim 1 , John J. Arcaroli 1 , Adrie Van Bokhoven 3 , M. Scott Lucia 3 , Francisco G. La Rosa 3 and Isabel R. Schlaepfer 1 1 Division of Medical Oncology, Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA 2 Department of Pharmacology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA 3 Department of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA Correspondence to: Isabel R. Schlaepfer, email: // Keywords : CPT1A, prostate cancer, enzalutamide, ranolazine, INPP5K Received : February 27, 2017 Accepted : April 10, 2017 Published : April 21, 2017 Abstract Prostate cancer (PCa) is the most common malignancy among Western men and the second leading-cause of cancer related deaths. For men who develop metastatic castration resistant PCa (mCRPC), survival is limited, making the identification of novel therapies for mCRPC critical. We have found that deficient lipid oxidation via carnitine palmitoyltransferase (CPT1) results in decreased growth and invasion, underscoring the role of lipid oxidation to fuel PCa growth. Using immunohistochemistry we have found that the CPT1A isoform is abundant in PCa compared to benign tissue (n=39, p<0.001) especially in those with high-grade tumors. Since lipid oxidation is stimulated by androgens, we have evaluated the synergistic effects of combining CPT1A inhibition and anti-androgen therapy. Mechanistically, we have found that decreased CPT1A expression is associated with decreased AKT content and activation, likely driven by a breakdown of membrane phospholipids and activation of the INPP5K phosphatase. This results in increased androgen receptor (AR) action and increased sensitivity to the anti-androgen enzalutamide. To better understand the clinical implications of these findings, we have evaluated fat oxidation inhibitors (etomoxir, ranolazine and perhexiline) in combination with enzalutamide in PCa cell models. We have observed a robust growth inhibitory effect of the combinations, including in enzalutamide-resistant cells and mouse TRAMPC1 cells, a more neuroendocrine PCa model. Lastly, using a xenograft mouse model, we have observed decreased tumor growth with a systemic combination treatment of enzalutamide and ranolazine. In conclusion, our results show that improved anti-cancer efficacy can be achieved by co-targeting the AR axis and fat oxidation via CPT1A, which may have clinical implications, especially in the mCRPC setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.17359

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 99

Metadata

Authors
Flaig, T. W., Salzmann-Sullivan, M., Su, L.-J., Zhang, Z., Joshi, M., Gijón, M. A., Kim, J., Arcaroli, J. J., Van Bokhoven, A., Lucia, M. S., La Rosa, F. G., & Schlaepfer, I. R.
Venue
Oncotarget
Published
2017-04-21
Volume
8
Issue
34
Pages
56051-56065
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2607413077
Cited by
99
References
7
FWCI
3.03
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.